Publications by authors named "Konstantinos Efthymiadis"
: Gastric cancer (GC) is the fifth leading cause of cancer-related mortality. CLDN18.2 is a tight junction protein, expressed in gastric mucosa and is considered as a novel therapeutic target.
View Article and Find Full Text PDFA retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management.
Photodermatol Photoimmunol Photomed
September 2023
Background: Limited data on immune checkpoint inhibitor (ICI)-induced pruritus per se and efficacy of different therapeutic modalities in its management exist.
Objective: To study the quantitative and qualitative characteristics of ICI-induced pruritus per se and to assess the efficacy of the therapeutic modalities usually applied.
Methods: We retrospectively reviewed the records of 91 patients who were under treatment with ICIs for any kind of neoplasia and developed pruritus during treatment.
Investigating Predictive Factors of Dysphagia and Treatment Prolongation in Patients with Oral Cavity or Oropharyngeal Cancer Receiving Radiation Therapy Concurrently with Chemotherapy.
Curr Oncol
May 2023
Radiation therapy (RT) treatment for head and neck cancer has been associated with dysphagia manifestation leading to worse outcomes and decrease in life quality. In this study, we investigated factors leading to dysphagia and treatment prolongation in patients with primaries arising from oral cavity or oropharynx that were submitted to radiation therapy concurrently with chemotherapy. The records of patients with oral cavity or oropharyngeal cancer that received RT treatment to the primary and bilateral neck lymph nodes concurrently with chemotherapy were retrospectively reviewed.
View Article and Find Full Text PDFNarrative Review of Drug-Associated Nail Toxicities in Oncologic Patients.
Dermatol Pract Concept
January 2023
Introduction: Nail toxicity represents one of the most common cutaneous adverse effects of both classic chemotherapeutic agents and new oncologic drugs, including targeted treatments and immunotherapy.
Objectives: We aimed to provide a comprehensive literature review of nail toxicities derived from conventional chemotherapeutic agents, targeted therapies (EGFR inhibitors, multikinase inhibitors, BRAF and MEK inhibitors) and immune checkpoint inhibitors (ICIs), including clinical presentation, implicated drugs and approaches for prevention and management.
Methods: Retrieved literature from PubMed registry database was reviewed to include all articles published up to May 2021 relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of oncologic treatment-induced nail toxicity.
Article Synopsis
- A European registry was established for patients with advanced EGFR exon 20-mutant non-small cell lung cancer (NSCLC) diagnosed between January 2019 and December 2021, specifically excluding those enrolled in clinical trials.* -
- The final analysis included data from 175 patients across nine countries, revealing a median age of 64 years, predominantly affecting women (56.3%) and mostly comprising adenocarcinoma cases (95.4%) with frequent bone (47.4%) and brain (32.0%) metastases.* -
- Treatment patterns varied significantly: chemotherapy and chemotherapy-immunotherapy combinations were used in 33.8% and 18.2% of cases respectively, with disease control rates of
Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals.
Dermatol Ther
July 2022
Article Synopsis
- Real-world analysis evaluated the long-term benefits of brodalumab for treating moderate-to-severe psoriasis in 180 Greek patients over 24 months.
- The study showed significant improvements in psoriasis severity (measured by PASI scores) and quality of life (measured by DLQI scores) from baseline, with high proportions of patients achieving major reductions in PASI scores as early as 1 month into treatment.
- Overall, the findings support brodalumab's effectiveness in standard clinical practice, highlighting its rapid and sustained positive impact on patients' conditions.
Article Synopsis
- The study examines factors that lead to dysphagia (difficulty swallowing) and the need for percutaneous gastrostomy (PEG) in head and neck cancer patients undergoing radiation therapy.
- Key predictive factors for severe dysphagia included higher radiation doses to the pharyngeal constrictor muscles, concurrent chemotherapy, and the presence of upper aerodigestive tract cancers.
- Patients identified as higher risk may benefit from close monitoring during treatment and potential prophylactic PEG placement, especially those receiving definitive therapies for certain cancer types.